These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 10611472)

  • 1. Differential block by troglitazone and rosiglitazone of glibenclamide-sensitive K(+) current in rat aorta myocytes.
    Mishra SK; Aaronson PI
    Eur J Pharmacol; 1999 Dec; 386(1):121-5. PubMed ID: 10611472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of insulin-sensitizers troglitazone and rosiglitazone on ion currents in rat vascular myocytes.
    Knock GA; Mishra SK; Aaronson PI
    Eur J Pharmacol; 1999 Feb; 368(1):103-9. PubMed ID: 10096775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Troglitazone has no effect on K(ATP) channel opener induced-relaxations in rat aorta and in human saphenous veins from patients with type 2 diabetes.
    Yöntem O; Sahilli M; Karasu C; Ozçelikay AT; Altan VM; Ari N
    Life Sci; 2000 Dec; 68(5):557-68. PubMed ID: 11197753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle.
    Eto K; Ohya Y; Nakamura Y; Abe I; Fujishima M
    Eur J Pharmacol; 2001 Jun; 423(1):1-7. PubMed ID: 11438300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic actions of insulin and troglitazone on contractility in endothelium-denuded rat aortic rings.
    Goud C; Pitt B; Webb RC; Richey JM
    Am J Physiol; 1998 Nov; 275(5):E882-7. PubMed ID: 9815009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Troglitazone, but not rosiglitazone, inhibits Na/H exchange activity and proliferation of macrovascular endothelial cells.
    de Dios ST; Hannan KM; Dilley RJ; Hill MA; Little PJ
    J Diabetes Complications; 2001; 15(3):120-7. PubMed ID: 11358680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide.
    Masuda K; Okamoto Y; Tsuura Y; Kato S; Miura T; Tsuda K; Horikoshi H; Ishida H; Seino Y
    Diabetologia; 1995 Jan; 38(1):24-30. PubMed ID: 7744225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro.
    Walker AB; Naderali EK; Chattington PD; Buckingham RE; Williams G
    Diabetes; 1998 May; 47(5):810-4. PubMed ID: 9588454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Troglitazone reduces contraction by inhibition of vascular smooth muscle cell Ca2+ currents and not endothelial nitric oxide production.
    Song J; Walsh MF; Igwe R; Ram JL; Barazi M; Dominguez LJ; Sowers JR
    Diabetes; 1997 Apr; 46(4):659-64. PubMed ID: 9075808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects among thiazolidinediones on the transcription of thromboxane receptor and angiotensin II type 1 receptor genes.
    Sugawara A; Takeuchi K; Uruno A; Ikeda Y; Arima S; Sato K; Kudo M; Taniyama Y; Ito S
    Hypertens Res; 2001 May; 24(3):229-33. PubMed ID: 11409645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuation by 4-aminopyridine of delayed vasorelaxation by troglitazone.
    Peuler JD; Warfield RK; Phelps LE
    Metabolism; 2004 Feb; 53(2):147-52. PubMed ID: 14767864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Troglitazone and pioglitazone attenuate agonist-dependent Ca2+ mobilization and cell proliferation in vascular smooth muscle cells.
    Asano M; Nakajima T; Iwasawa K; Morita T; Nakamura F; Imuta H; Chisaki K; Yamada N; Omata M; Okuda Y
    Br J Pharmacol; 1999 Oct; 128(3):673-83. PubMed ID: 10516648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Troglitazone, a new antidiabetic agent possessing radical scavenging ability, improved decreased skin blood flow in diabetic rats.
    Fujiwara T; Ohsawa T; Takahashi S; Ikeda K; Okuno A; Ushiyama S; Matsuda K; Horikoshi H
    Life Sci; 1998; 63(22):2039-47. PubMed ID: 9839548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Troglitazone and metformin, but not glibenclamide, decrease blood pressure in Otsuka Long Evans Tokushima Fatty rats.
    Kosegawa I; Chen S; Awata T; Negishi K; Katayama S
    Clin Exp Hypertens; 1999 Apr; 21(3):199-211. PubMed ID: 10225476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Troglitazone inhibits angiotensin II-induced DNA synthesis and migration in vascular smooth muscle cells.
    Graf K; Xi XP; Hsueh WA; Law RE
    FEBS Lett; 1997 Jan; 400(1):119-21. PubMed ID: 9000525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone.
    Yamazaki H; Suzuki M; Tane K; Shimada N; Nakajima M; Yokoi T
    Xenobiotica; 2000 Jan; 30(1):61-70. PubMed ID: 10659951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Troglitazone inhibits type 2KATP channel activity and depolarises tolbutamide-sensitive neurones in the rat ventromedial hypothalamus.
    Lee K; Boden P
    Brain Res; 1997 Mar; 751(1):165-8. PubMed ID: 9098583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of KATP channel activity by troglitazone in CRI-G1 insulin-secreting cells.
    Lee K; Ibbotson T; Richardson PJ; Boden PR
    Eur J Pharmacol; 1996 Oct; 313(1-2):163-7. PubMed ID: 8905344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Troglitazone and rosiglitazone inhibit the low density lipoprotein-induced vascular smooth muscle cell growth.
    Gouni-Berthold I; Berthold HK; Weber AA; Seul C; Vetter H; Sachinidis A
    Exp Clin Endocrinol Diabetes; 2001; 109(4):203-9. PubMed ID: 11453032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open channel block of Kv1.3 by rosiglitazone and troglitazone: Kv1.3 as the pharmacological target for rosiglitazone.
    Ahn HS; Kim SE; Jang HJ; Kim MJ; Rhie DJ; Yoon SH; Jo YH; Kim MS; Sung KW; Kim SY; Hahn SJ
    Naunyn Schmiedebergs Arch Pharmacol; 2007 Jan; 374(4):305-9. PubMed ID: 17119927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.